-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroSense plans head-to-head PrimeC trial versus Mitsubishi Tanabe’s edaravone in ALS

PUBT·08/31/2026 12:45:31
Listen to the news
NeuroSense plans head-to-head PrimeC trial versus Mitsubishi Tanabe’s edaravone in ALS
  • NeuroSense outlined a redesigned development plan for PrimeC in ALS, aiming to speed a regulatory filing while cutting overall development costs.
  • Phase 2b PARADIGM results were already reported, supporting the program with signs of clinical benefit, biomarker changes, and longer-term survival trends.
  • Next steps include an active-comparator trial versus edaravone, seeking clearer differentiation to support commercial positioning with physicians and payers.
  • A smaller, shorter Phase 3 PARAGON design is under review, with FDA discussions planned on full approval versus accelerated approval.
  • Canada filing targeted for December 2026, which could bring earlier market access based on existing data if accepted and approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608310845PR_NEWS_USPR_____LN36856) on August 31, 2026, and is solely responsible for the information contained therein.